Cibinqo Approved to Treat Atopic Dermatitis
January 14, 2022
One Batch of Semglee Recalled Due to Missing Label
January 19, 2022
January 14, 2022 – AbbVie's Rinvoq® (upadacitinib) has been approved to treat moderate to severe atopic dermatitis (AD) in patients at least 12 years old who have refractory disease not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
- Recommended dosing is 15mg taken by mouth once daily. For certain patients, the dosage may be increased to 30mg once daily if an adequate response is not achieved at 15mg a day.
- Rinvoq first received FDA approval in 2019 and is also indicated to treat rheumatoid arthritis and psoriatic arthritis.